Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

180
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
180
Chronic Bowel Disorders: Introduction01:17

Chronic Bowel Disorders: Introduction

634
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
634
Acute Pancreatitis II: Clinical Manifestations and Management01:30

Acute Pancreatitis II: Clinical Manifestations and Management

439
Acute pancreatitis presents a complex medical emergency characterized by rapid onset inflammation of the pancreas, demanding timely diagnosis and management to prevent complications. The condition primarily manifests through severe upper abdominal pain that often radiates to the back. This pain intensifies following the consumption of fatty foods. Accompanying symptoms such as nausea, vomiting, abdominal distention, fever, dyspnea, cyanosis, and jaundice can vary in intensity but significantly...
439
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

2.4K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.4K
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

300
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
300
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

235
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
235

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

New Treatment Options for MASLD Patients with Type 2 Diabetes.

Life (Basel, Switzerland)·2026
Same author

Sex Hormones and the Liver: Implications for Disease Progression and Hormonal Therapy.

Liver international : official journal of the International Association for the Study of the Liver·2026
Same author

Reply: Competing risk and surveillance thresholds for HCC in patients with PSC.

Hepatology (Baltimore, Md.)·2025
Same author

Primary biliary cholangitis (PBC): evolving approaches and expert perspectives.

Expert review of gastroenterology & hepatology·2025
Same author

Adherence, satisfaction, and quality of life in Wilson disease patients after switching to trientine tetrahydrochloride: observational data from a dual cohort study.

Frontiers in pharmacology·2025
Same author

An update on novel investigational agents for the treatment of primary biliary cholangitis.

Expert opinion on investigational drugs·2025

Related Experiment Video

Updated: Nov 20, 2025

Partial Bile Duct Ligation in the Mouse: A Controlled Model of Localized Obstructive Cholestasis
04:38

Partial Bile Duct Ligation in the Mouse: A Controlled Model of Localized Obstructive Cholestasis

Published on: March 28, 2018

16.2K

Primary biliary cholangitis: treatment.

Nora Cazzagon1, Annarosa Floreani2,3

  • 1Department of Surgery, Oncology and Gastroenterology.

Current Opinion in Gastroenterology
|January 25, 2021
PubMed
Summary
This summary is machine-generated.

For primary biliary cholangitis (PBC) patients with inadequate response to ursodeoxycholic acid (UDCA), second-line therapies like obeticholic acid or bezafibrate offer improved outcomes. Budesonide and triple therapy are also considered for advanced cases.

Related Experiment Videos

Last Updated: Nov 20, 2025

Partial Bile Duct Ligation in the Mouse: A Controlled Model of Localized Obstructive Cholestasis
04:38

Partial Bile Duct Ligation in the Mouse: A Controlled Model of Localized Obstructive Cholestasis

Published on: March 28, 2018

16.2K

Area of Science:

  • Hepatology
  • Gastroenterology
  • Internal Medicine

Background:

  • Primary biliary cholangitis (PBC) is a chronic liver disease.
  • Ursodeoxycholic acid (UDCA) is the standard first-line treatment.
  • A subset of patients exhibit an inadequate response to UDCA, necessitating alternative therapies.

Purpose of the Study:

  • To review recent data on second-line treatments for PBC patients with inadequate UDCA response.
  • To identify high-risk patient groups requiring intensified treatment strategies.
  • To discuss therapeutic goals including normalization of liver enzymes and bilirubin levels.

Main Methods:

  • Review of current clinical trial data and real-world evidence.
  • Analysis of surrogate markers for disease progression and treatment efficacy.
  • Evaluation of adverse event profiles for second-line agents.

Main Results:

  • Obeticholic acid (OCA) improves prognostic markers in PBC, with pruritus as a common side effect.
  • Bezafibrate demonstrates efficacy in improving surrogate endpoints and clinical outcomes compared to UDCA monotherapy.
  • Budesonide may benefit patients with significant portal inflammation; triple therapy is an option for refractory cases.

Conclusions:

  • Patients with PBC require ongoing risk assessment and may benefit from second-line therapies beyond UDCA.
  • OCA, bezafibrate, and budesonide represent key options for optimizing PBC management.
  • Personalized treatment approaches, including combination therapies, are crucial for improving patient outcomes.